Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Zura Bio LimitedNASDAQ: ZURA
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow declines year over year
Q1 FY2026 investing cash flow of $13K (cash outflow) fell 73.5% year over year, behind the -34.2% change in trailing-twelve-month investing cash flow. Sequentially, it fell 23.5% from the prior quarter. Over 3 fiscal years it compounded at -78.9% a year.
Context
- Investing cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -73.5% toward the trailing-twelve-month pace of -34.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (113K) USD
- Year-over-year change
- +97.8%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (113K) | +97.8% |
| FY2024 | 2024-12-31 | (5.08M) | +36.6% |
| FY2023 | 2023-12-31 | (8M) | +33.3% |
| FY2022 | 2022-12-31 | (12M) | +91.4% |
| FY2021 | 2021-12-31 | (139.38M) | — |
Investing Cash Flow vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's LTM Mar 2026 investing cash flow of $77K is the 10th largest of the 11 companies compared; the peer median is $20.65M.
- Its year-over-year change of -34.2% is the 6th highest of 11, against a peer median of -15.9%.
- Over three fiscal years its annual growth of -78.9% compares with a peer median of -11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.8M | -3115.8% | — | — | |
| LTM Mar 2026 | $125.44M | -525.4% | — | 176.4% | |
| LTM Mar 2026 | $97.21M | +178.0% | +267.6% | — | |
| LTM Mar 2026 | $64.92M | +335.2% | — | 230.0% | |
| LTM Mar 2026 | $59.54M | -177.1% | -9.8% | 86.0% | |
| LTM Mar 2026 | $59.41M | +39.9% | — | 428.7% | |
| LTM Mar 2026 | $33.77M | +20.9% | -12.5% | 15008.9% | |
| LTM Mar 2026 | $29.95M | -52.8% | — | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $11.36M | +118.5% | — | — |
ZURAZura Bio Limited | LTM Mar 2026 | $77K | -34.2% | -78.9% | — |
| LTM Mar 2026 | $59.66K | -89.1% | -69.0% | 0.1% | |
| Peer median (excluding ZURA) | $20.65M | -15.9% | -11.1% | 203.2% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 334K | 9.66M | 16.8M | 12.33M |
| Change in Working Capital | (235.6K) | 3.54M | 5.12M | 2.31M | (3.63M) |
| Accounts Receivables | 2.87K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 288.29K | 0 | 4.21M | (2.16M) |
| Other Working Capital | (238.47K) | 3.25M | 5.12M | (1.91M) | (1.47M) |
| Other Non-Cash Items | (9.28M) | 22.26M | 30.74M | 5.21M | (4.91M) |
| Operating Cash Flow | (1.1M) | (1.2M) | (15.05M) | (28.08M) | (64.82M) |
| Capital Expenditures | (4) | (12M) | (8M) | (75K) | (113K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (139.38M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (5M) | 0 |
| Investing Cash Flow | (139.38M) | (12M) | (8M) | (5.08M) | (113K) |
| Debt Repayment | (117.38K) | 7.6M | (10M) | 0 | 0 |
| Common Stock Issued | 140.82M | 0 | 116.41M | 60.76M | 5.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 505K | (2.83M) | 14.89M | 49.09M | (7.37M) |
| Financing Cash Flow | 141.21M | 14.77M | 121.29M | 109.84M | (2.16M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 729.22K | 1.57M | 98.24M | 76.69M | (67.09M) |
| Free Cash Flow | (1.1M) | (13.2M) | (23.05M) | (28.15M) | (64.93M) |
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.